TELA Valuation

TELA Bio Inc

Add to Watchlist

Advanced Chart

1.700

+0.12(7.595%)1D

Overview
Forecast
Valuation
Earnings

TELA Relative Valuation

TELA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TELA is overvalued; if below, it's undervalued.

Historical Valuation

TELA Bio Inc (TELA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.66 is considered Undervalued compared with the five-year average of -4.81. The fair price of TELA Bio Inc (TELA) is between 5.16 to 14.31 according to relative valuation methord. Compared to the current price of 1.70 USD , TELA Bio Inc is Undervalued By 67.04%.

Relative Value

Fair Zone

5.16-14.31

Current Price：1.70

67.04%

Undervalued

-2.36

Trailing

Forward

-3.34

EV/EBITDA

TELA Bio Inc. (TELA) has a current EV/EBITDA of -3.34. The 5-year average EV/EBITDA is -5.85. The thresholds are as follows: Strongly Undervalued below -10.40, Undervalued between -10.40 and -8.12, Fairly Valued between -3.57 and -8.12, Overvalued between -3.57 and -1.29, and Strongly Overvalued above -1.29. The current Forward EV/EBITDA of -3.34 falls within the Overvalued range.

-2.44

EV/EBIT

TELA Bio Inc. (TELA) has a current EV/EBIT of -2.44. The 5-year average EV/EBIT is -4.56. The thresholds are as follows: Strongly Undervalued below -7.41, Undervalued between -7.41 and -5.98, Fairly Valued between -3.14 and -5.98, Overvalued between -3.14 and -1.71, and Strongly Overvalued above -1.71. The current Forward EV/EBIT of -2.44 falls within the Overvalued range.

0.66

TELA Bio Inc. (TELA) has a current PS of 0.66. The 5-year average PS is 3.44. The thresholds are as follows: Strongly Undervalued below -1.00, Undervalued between -1.00 and 1.22, Fairly Valued between 5.67 and 1.22, Overvalued between 5.67 and 7.89, and Strongly Overvalued above 7.89. The current Forward PS of 0.66 falls within the Undervalued range.

0.00

P/OCF

TELA Bio Inc. (TELA) has a current P/OCF of 0.00. The 5-year average P/OCF is -0.42. The thresholds are as follows: Strongly Undervalued below -18.89, Undervalued between -18.89 and -9.66, Fairly Valued between 8.82 and -9.66, Overvalued between 8.82 and 18.06, and Strongly Overvalued above 18.06. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

TELA Bio Inc. (TELA) has a current P/FCF of 0.00. The 5-year average P/FCF is -5.67. The thresholds are as follows: Strongly Undervalued below -58.73, Undervalued between -58.73 and -32.20, Fairly Valued between 20.87 and -32.20, Overvalued between 20.87 and 47.40, and Strongly Overvalued above 47.40. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

TELA Bio Inc (TELA) has a current Price-to-Book (P/B) ratio of 6.81. Compared to its 3-year average P/B ratio of 8.89 , the current P/B ratio is approximately -23.42% higher. Relative to its 5-year average P/B ratio of 5.49, the current P/B ratio is about 24.12% higher. TELA Bio Inc (TELA) has a Forward Free Cash Flow (FCF) yield of approximately -55.40%. Compared to its 3-year average FCF yield of -36.19%, the current FCF yield is approximately 53.07% lower. Relative to its 5-year average FCF yield of -28.25% , the current FCF yield is about 96.07% lower.

6.81

P/B

Median3y

8.89

Median5y

5.49

-55.40

FCF Yield

Median3y

-36.19

Median5y

-28.25

Competitors Valuation Multiple

The average P/S ratio for TELA's competitors is 4.47, providing a benchmark for relative valuation. TELA Bio Inc Corp (TELA) exhibits a P/S ratio of 0.66, which is -85.23% above the industry average. Given its robust revenue growth of 25.52%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Sensus Healthcare Inc

Performance Decomposition

Market capitalization of TELA decreased by 41.38% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 16.09M to 20.20M.

The secondary factor is the P/E Change, contributed -29.65%to the performance.

Overall, the performance of TELA in the past 1 year is driven by Revenue Growth. Which is more sustainable.

25.52%

16.09M → 20.20M

Revenue Growth

-37.25%

-78.30 → -49.13

Margin Expansion

-29.65%

-2.14 → -1.51

P/E Change

-41.38%